** Shares of Emergent BioSolutions rise 12.6% to $6.88 premarket
** Co says it has secured about $400 mln in orders for 2024 and 2025 for its vaccinia virus, smallpox and mpox vaccines
** EBS says this includes the previously disclosed contract from the U.S. government to procure the vaccines, valued at more than $250 mln
** Says to date in 2024, customer orders of nearly $210 mln have been delivered for ACAM2000 - its smallpox and mpox vaccine - and CNJ-016 - its vaccine for vaccinia virus
** For the remainder of 2024 and into 2025, co says it is confirmed to deliver over $185 mln in ACAM2000 and CNJ-016 orders
** Up to last close, stock more than doubled YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.